LAUSR

Key Points Question Among adults with type 2 diabetes (T2D), what is the efficacy, safety, and tolerability of the novel, orally administered, small molecule glucagon-like peptide 1 receptor agonist danuglipron? Findings In this phase 2 randomized clinical trial in 411 adults with T2D, danuglipron reduced glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16 compared with placebo, with the most commonly reported adverse events being gastrointestinal in nature. Meaning In this study of patients with T2D, danuglipron demonstrated an efficacy and safety profile consistent with peptidic glucagon-like peptide 1 receptor agonists, without injection or fasting restrictions.